Apr 18, 2019 4:01pm EDT Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
Apr 02, 2019 8:00am EDT Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
Apr 01, 2019 8:00am EDT Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
Feb 27, 2019 12:05pm EST CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
Feb 27, 2019 7:29am EST Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
Feb 07, 2019 8:00am EST Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
Jan 07, 2019 7:30am EST Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
Oct 25, 2018 4:30pm EDT Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
